Developing Human Immunotherapies

Jan 11, 2019

Blaine Crissman
Credit Adria Botella

Blaine Crissman is with South Dakota Equity Partners and Eddie Sullivan is with SAB Biotherapeutics. SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing human immunotherapies. SDEP is investing $1 million dollars in SAB. This is the first investment made by the new private equity fund focusing on South Dakota growth-stage companies.

Eddie Sullivan
Credit Adria Botella